申请人:Sumitomo Pharmaceuticals Company Limited
公开号:US06645971B1
公开(公告)日:2003-11-11
A compound given by general formula (1):
[wherein T represents oxygen or sulfur atom, Y represents alkyl, cycloalkyl group, etc., ring W represents benzene ring, etc., R1 and R2 represent independently hydrogen atom, lower alkyl group, etc., and R3 represents hydrogen atom, alkyl group, etc. Z represents a group given by formula:
{wherein A1 and A2 represent independently hydrogen atom, alkyl group, etc. and G represents straight chain alkylene having 1-6 of the carbon number, etc.} or a group given by formula:
{wherein n represents 0, 1 or 2, ring E represents 4-8 membered saturated heterocyclic ring containing nitrogen atom(s), and A3 represents hydrogen atom, alkyl group, etc.}], its prodrug or pharmaceutically acceptable salt thereof is an antagonist against muscarinic receptor that is useful as anticholinergic medicaments, and therefore it is useful as pollakiuria or urinary incontinence remedy.
一种由通式(1)表示的化合物:[其中T表示氧或硫原子,Y表示烷基、环烷基等,环W表示苯环等,R1和R2独立地表示氢原子、低级烷基等,R3表示氢原子、烷基等。Z表示由以下公式给出的基团:其中A1和A2独立地表示氢原子、烷基等,G表示具有1-6个碳原子的直链亚烷基等}或由以下公式给出的基团:其中n表示0、1或2,环E表示含有氮原子的4-8元饱和杂环,A3表示氢原子、烷基等},其前药或其药学上可接受的盐是毒蕈碱受体的拮抗剂,可用作抗胆碱能药物,因此它可作为尿频或尿失禁的治疗药物。